Incyte

Press Releases
Contact
Board of Directors 

Richard U. De Schutter, Chairman of the Board
Former Chairman and Chief Executive Officer
DuPont Pharmaceuticals

Barry M. Ariko 
President, Chief Executive Officer and Chairman
Mirapoint, Inc.

Julian C. Baker
Managing Member
Baker Bros. Advisors, LLC 

Paul A. Brooke 
Chairman and Chief Executive Officer, Ithaka Acquisition Corp.
Managing Member, PMSV Holdings, LLC 
Advisory Director, Morgan Stanley
Venture Partner, MPM Capital 

Paul A. Friedman, M.D.
President and Chief Executive Officer
Incyte Corporation

John F. Niblack, Ph.D.
Former Vice Chairman and President of Global Research and Development
Pfizer Inc

Roy A. Whitfield
Former Chairman and Chief Executive Officer
Incyte Corporation


Top Richard U. De Schutter

Former Chairman and Chief Executive Officer
DuPont Pharmaceuticals
  

Richard U. De Schutter  was Chairman and Chief Executive Officer of DuPont Pharmaceuticals Company from July 2000 to October 2001.  He served as Chief Administrative Officer at Pharmacia Corporation between April 2000 and July 2000.  From January 1999 through March 2000, Mr. De Schutter served as Vice Chairman and Chief Administrative Officer of Monsanto Company. He served as Chief Executive Officer of G.D. Searle & Co. from April 1995 to December 1998.  Mr. De Schutter is also a director of Ecolab, Inc., Smith & Nephew PLC, Varian, Inc. and several privately held companies.


Top Barry M. Ariko

President, Chief Executive Officer and Chairman
Mirapoint, Inc.
 

Barry M. Ariko has been President and Chief Executive Officer of Mirapoint, Inc., a private technology company that produces infrastructure for managing and securing Internet messaging, since November 2003, and has been Chairman of the Board of Mirapoint since December 2003.  He was a private consultant from October 2001 to October 2003.  From April 2001 until September 2001, Mr. Ariko was Senior Vice President of Peregrine Systems, Inc., an infrastructure management software company, and from April 2001 until June 2002 was a member of its Board of Directors.  From March 2000 until the acquisition of Extricity, Inc. by Peregrine in April 2001, Mr. Ariko served as the President and Chief Executive Officer of Extricity, a private Internet software provider, and he also served as Chairman of the Board of Extricity from March 2000 to April 2001.  In September 2002, Peregrine filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware.  Peregrine emerged from bankruptcy court supervision in August 2003 and was acquired by Hewlett-Packard Company in December 2005.  From March 1999 to January 2000, Mr. Ariko was a Senior Vice President of America Online, Inc., where he was responsible for the Netscape Enterprise Group. From August 1998 until the acquisition of Netscape Communications Corporation by America Online in March 1999, Mr. Ariko served as Executive Vice President and Chief Operating Officer of Netscape. From 1994 to August 1998, Mr. Ariko was Executive Vice President of Oracle Corporation.  Mr. Ariko currently serves as a director of Autonomy Corporation plc and a privately held company.


TopJulian C. Baker

Managing Member
Baker Bros. Advisors, LLC
 

Julian C. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker’s firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies.  Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation.  He is also a director of Genomic Health, Inc., Neurogen Corporation, Theravance, Inc. and Trimeris, Inc.


TopPaul A. Brooke

Chairman and Chief Executive Officer, Ithaka Acquisition Corp.
Managing Member, PMSV Holdings, LLC 
Advisory Director, Morgan Stanley
Venture Partner, MPM Capital 

Paul A. Brooke has been Chairman of the Board of Directors and Chief Executive Officer of Ithaka Acquisition Corp., a special purpose acquisition company whose objective is to acquire an operating business in the healthcare industry, since 2005 and a Managing Member of PMSV Holdings LLC, a private investment firm, since 1993.  He has also served as an Advisory Director of Morgan Stanley & Co. Incorporated and Skyline Partners since April 2000, and as a Venture Partner at MPM Capital, a venture capital firm specializing in the healthcare industry, since 1997. From April 1999 through May 2000, Mr. Brooke served as a Managing Director at Tiger Management LLC.  He was a Managing Director and the Global Head of Healthcare Research and Strategy at Morgan Stanley & Co. from 1983 to April 1999.  Mr. Brooke is also a director of ViroPharma Incorporated, WebMD Corporation and several privately held companies.


TopPaul A. Friedman, M.D.

President and Chief Executive Officer
Incyte Corporation

Paul A. Friedman, M.D.  joined the Company as the Chief Executive Officer in November 2001 and has been President of the Company since May 2004. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a Diplomate of the American Board of Internal Medicine, Member of the American Society of Pharmacology and Experimental Therapeutics, Member of the American Society of Clinical Investigation and a Member of the American Society of Biological Chemists. Dr. Friedman is also a director of Bausch & Lomb Incorporated.


Top 

John F. Niblack, Ph.D.

Former Vice Chairman and President of Global Research and Development
Pfizer Inc

John F. Niblack, Ph.D.  retired from Pfizer Inc. in September 2002, where he had served as its Vice Chairman since May 1999. From June 2000 to July 2002, he also served as President of Pfizer Global Research and Development. Dr. Niblack was Executive Vice President of Pfizer from 1993 to May 1999 and was responsible for Pfizer’s Global Research and Development Division and Pharmaceutical Licensing and Development.  Dr. Niblack held other various positions at Pfizer since 1967

Top


Roy A. Whitfield

Former Chairman and Chief Executive Officer
Incyte Corporation
 
Roy A. Whitfield co-founded the Company and served as Chairman of the Board from November 2001 until June 2003. Mr. Whitfield served as Chief Executive Officer of the Company between June 1993 and November 2001, as President of the Company from June 1991 until January 1997, and as Treasurer of the Company between April 1991 and October 1995. Previously, Mr. Whitfield served as the President of Ideon Corporation, which was a majority-owned subsidiary of Invitron Corporation, a biotechnology company, from October 1989 until April 1991. From 1984 to 1989, he held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Prior to his work at Technicon, Mr. Whitfield spent seven years with the Boston Consulting Group’s international consulting practice. He also serves as a director of Nektar Therapeutics and several privately held companies.

Source: Incyte 2006 Proxy Statement
 

 

Top 
 

©Copyright 2008 Incyte Corporation Incyte